Regulatory and Safety Aspects of Cell and Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

 

  • guidelines of cell therapy
  • safety precautions

Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

June 15-16, 2020

24th Global Congress on Biotechnology

London, UK
July 15-16, 2020

12th World Congress and Expo on Stem Cell Research

Prague, Czech Republic
July 15-16, 2020

25th World Biotechnology Congress

London, UK
September 21-22, 2020

14th International Conference on Genomics & Pharmacogenomics

Vancouver, Canada
September 23-24, 2020

24th European Biotechnology Congress

Berlin, Germany
October 19-20, 2020

7th Asia Pacific Geriatrics and Gerontology Congress

Tokyo, Japan
October 23-24, 2020

2nd International Conference on Biomarkers and Cancer Targets

Cape Town, South Africa
November 16-17, 2020

International Conference on Genomics and Molecular Biology

Lisbon, Portugal
November 19-20, 2020

24th European Biotechnology Congress (EBC_2020)

London, UK
November 23-24, 2020

International Conference on Toxicogenomics

Bali, Indonesia
December 07-08, 2020

2nd World Congress on Cell and Structural Biology

Sydney, Australia

Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in